These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37558377)

  • 1. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
    Nelson K; Fuster V; Ridker PM
    J Am Coll Cardiol; 2023 Aug; 82(7):648-660. PubMed ID: 37558377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
    Burger PM; Dorresteijn JAN; Fiolet ATL; Koudstaal S; Eikelboom JW; Nidorf SM; Thompson PL; Cornel JH; Budgeon CA; Westendorp ICD; Beelen DPW; Martens FMAC; Steg PG; Asselbergs FW; Cramer MJ; Teraa M; Bhatt DL; Visseren FLJ; Mosterd A; ; ;
    Eur J Prev Cardiol; 2023 Dec; 30(18):1950-1962. PubMed ID: 37409348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Ridker PM
    Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation.
    Zhang RS; Weber BN; Araiza-Garaygordobil D; Garshick MS
    Curr Cardiol Rep; 2024 May; 26(5):423-434. PubMed ID: 38573553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine in Stable Coronary Artery Disease.
    Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
    Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Nidorf SM; Fiolet ATL; Eikelboom JW; Schut A; Opstal TSJ; Bax WA; Budgeon CA; Tijssen JGP; Mosterd A; Cornel JH; Thompson PL;
    Am Heart J; 2019 Dec; 218():46-56. PubMed ID: 31706144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention.
    Ridker PM
    Vascul Pharmacol; 2023 Dec; 153():107238. PubMed ID: 37871757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.
    Montarello NJ; Singh K; Sinhal A; Wong DTL; Alcock R; Rajendran S; Dautov R; Barlis P; Patel S; Nidorf SM; Thompson PL; Salagaras T; Butters J; Nerlekar N; Di Giovanni G; Ottaway JL; Nicholls SJ; Psaltis PJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1175-1186. PubMed ID: 34432196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent clinical studies of the effects of lipid-modifying therapies.
    Gotto AM; Moon JE
    Am J Cardiol; 2012 Jul; 110(1 Suppl):15A-26A. PubMed ID: 22697388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aspirin, statins, colchicine, and IL-1 inhibitors in prevention of cardiovascular events: a systematic integrative review.
    Arboleda V; Hackworth A; Bonnice S; Gonzalez V; Cabrera D; Colletti C; Baxter C; Aleman Oliva C; Kabir S; Huang J; Khan A; Filoramo S; Ecoff S; Demory Beckler M; Kesselman MM
    J Osteopath Med; 2024 Mar; 124(3):97-106. PubMed ID: 37877246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.